Form 4: Dermata CFO Granted 18,000 Stock Options

Dermata Therapeutics' SVP and CFO, Kyri K. Van Hoose, was granted 18,000 stock options with an exercise price of $2.18, vesting over four years.

Summary

• Kyri K. Van Hoose, the Senior Vice President and Chief Financial Officer of Dermata Therapeutics, Inc. (DRMA), was granted stock options.
• The transaction date for the option grant was January 2, 2026.
• A total of 18,000 derivative securities, specifically stock options, were acquired.
• Each option has an exercise price of $2.18.
• The options allow the holder to purchase 18,000 shares of Dermata Therapeutics' Common Stock.
• The options have an expiration date of January 1, 2036.
• The vesting schedule for these options is as follows: 25% will vest on the 12-month anniversary of the grant date (January 2, 2027), and the remaining 75% will vest in 36 equal monthly installments commencing on the 12-month anniversary of the grant date.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating management alignment with shareholder interests and a commitment to long-term performance. It is a routine compensation event, not indicative of significant operational changes.

Positives

• The grant of stock options to a key executive like the CFO aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options have a long expiration date of January 1, 2036, providing a significant window for the company's stock price to appreciate.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider's equity transaction.

Industry Context

The grant of stock options to senior executives is a standard practice in the biotechnology and pharmaceutical industries, including companies like Dermata Therapeutics, to attract, retain, and motivate key talent by linking their compensation to the company's long-term stock performance.

Comparison to Industry Standards

• The vesting schedule, with a one-year cliff followed by monthly installments over three years, is a common structure for executive stock option grants in the biotech sector, similar to practices seen at companies like Moderna or BioNTech for their senior leadership.
• An exercise price of $2.18, likely the market price on the grant date, is standard for incentive stock options, ensuring the executive benefits only if the stock price appreciates from that point.

Stakeholder Impact

• Shareholders: The grant aligns the CFO's financial interests with shareholder value creation, as the options gain value only if the stock price increases.
• Employees: May signal stability in executive leadership and a standard approach to executive compensation.

Next Steps

• The stock options will begin to vest on January 2, 2027, with 25% vesting on that date.
• The remaining 75% of the options will vest in 36 equal monthly installments starting from January 2, 2027.

Key Dates

Keywords

Dermata Therapeutics, DRMA, Stock Options, Insider Transaction, SEC Form 4, Executive Compensation, Kyri K. Van Hoose, CFO